Evidence map›Paper›PMID 38108546›Full record

ReviewAllergy2024

Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology.

F Roth-Walter, I M Adcock, C Benito-Villalvilla, R Bianchini, L Bjermer, G Caramori, L Cari, K F Chung, Z Diamant, I Eguiluz-Gracia and 10 more

Open access · hybridAbstract readReviewConsensus Statement
In one paragraph

Review in Allergy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 12 countries.

F Roth-WalterComparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria.ORCID 0000-0001-5005-9228
I M AdcockMolecular Cell Biology Group, National Heart & Lung Institute, Imperial College London, London, UK.ORCID 0000-0003-2101-8843
C Benito-VillalvillaDepartment of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.ORCID 0000-0002-5544-0199
R BianchiniComparative Medicine, The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria.ORCID 0000-0003-0351-6937
L BjermerDepartment of Respiratory Medicine and Allergology, Lung and Allergy research, Allergy, Asthma and COPD Competence Center, Lund University, Lund, Sweden.ORCID 0000-0002-3441-8099
G CaramoriDepartment of Medicine and Surgery, University of Parma, Pneumologia, Italy.ORCID 0000-0002-9807-327X
L CariDepartment of Medicine, Section of Pharmacology, University of Perugia, Perugia, Italy.ORCID 0000-0003-0698-3872
K F ChungExperimental Studies Medicine at National Heart & Lung Institute, Imperial College London & Royal Brompton & Harefield Hospital, London, UK.ORCID 0000-0001-7101-1426
Z DiamantDepartment of Respiratory Medicine and Allergology, Institute for Clinical Science, Skane University Hospital, Lund, Sweden.ORCID 0000-0003-0133-0100
I Eguiluz-GraciaAllergy Unit, Hospital Regional Universitario de Málaga-Instituto de Investigación Biomédica de Málaga (IBIMA)-ARADyAL, Málaga, Spain.ORCID 0000-0002-3774-931X
E F KnolDepartments of Center of Translational Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0001-7368-9820
M JesenakDepartment of Paediatrics, Department of Pulmonology and Phthisiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, University Teaching Hospital, Martin, Slovakia.ORCID 0000-0001-7976-2523
F Levi-SchafferInstitute for Drug Research, Pharmacology Unit, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID 0000-0003-0620-2810
G NocentiniDepartment of Medicine, Section of Pharmacology, University of Perugia, Perugia, Italy.ORCID 0000-0002-5209-0488
L O'MahonyAPC Microbiome Ireland, University College Cork, Cork, Ireland.ORCID 0000-0003-4705-3583
O PalomaresDepartment of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.ORCID 0000-0003-4516-0369
F RedegeldDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0001-8830-7960
M SokolowskaSwiss Institute of Allergy and Asthma Research (SIAF), University of Zürich, Davos, Switzerland.ORCID 0000-0001-9710-6685
B C A M Van EschDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0001-9961-750X
C StellatoDepartment of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.ORCID 0000-0002-1294-8355
Universidad Complutense de Madrid · ESUniversity of Perugia · ITUniversity of Veterinary Medicine Vienna · ATUtrecht University · NLComenius University Bratislava · SKHarefield Hospital · GBHebrew University of Jerusalem · ILHospital Regional Universitario de Málaga · ESLund University · SELung Institute · USUniversity College Cork · IEUniversity Medical Center Groningen · NLUniversity Medical Center Utrecht · NLUniversity of Parma · ITUniversity of Salerno · ITUniversity of Zurich · CH

Funding

Aimwell Charitable TrustAustrian Science Fund FWF project SFB F4606-B28Danube Allergy Research Cluster-DARC #08Emalie Gutterman Memorial Endowed FundEPSRC (EP/T003189/1)European Academy for Allergy and Clinical ImmunologyInstituto de Salud Carlos III of the Spanish Ministry of Economy and CompetitivenessIsrael Science FoundationMICIIN (PID2020-114396RB-I00)Ministero dell'Istruzione, dell'Università e della RicercaMRC (MR/T010371/1)NovartisStiftung vorm. Bündner Heilstätte ArosaSwiss National Science Foundation (SNSF nr 310030_189334/1)University of Messina, Sicilia RegionUniversity of Salerno and Campania Region
6 · The paper itself

Abstract

The accumulation of senescent cells drives inflammaging and increases morbidity of chronic inflammatory lung diseases. Immune responses are built upon dynamic changes in cell metabolism that supply energy and substrates for cell proliferation, differentiation, and activation. Metabolic changes imposed by environmental stress and inflammation on immune cells and tissue microenvironment are thus chiefly involved in the pathophysiology of allergic and other immune-driven diseases. Altered cell metabolism is also a hallmark of cell senescence, a condition characterized by loss of proliferative activity in cells that remain metabolically active. Accelerated senescence can be triggered by acute or chronic stress and inflammatory responses. In contrast, replicative senescence occurs as part of the physiological aging process and has protective roles in cancer surveillance and wound healing. Importantly, cell senescence can also change or hamper response to diverse therapeutic treatments. Understanding the metabolic pathways of senescence in immune and structural cells is therefore critical to detect, prevent, or revert detrimental aspects of senescence-related immunopathology, by developing specific diagnostics and targeted therapies. In this paper, we review the main changes and metabolic alterations occurring in senescent immune cells (macrophages, B cells, T cells). Subsequently, we present the metabolic footprints described in translational studies in patients with chronic asthma and chronic obstructive pulmonary disease (COPD), and review the ongoing preclinical studies and clinical trials of therapeutic approaches aiming at targeting metabolic pathways to antagonize pathological senescence. Because this is a recently emerging field in allergy and clinical immunology, a better understanding of the metabolic profile of the complex landscape of cell senescence is needed. The progress achieved so far is already providing opportunities for new therapies, as well as for strategies aimed at disease prevention and supporting healthy aging.

Indexed as

Cellular SenescenceMetabolic Networks and PathwaysAgingAnimalsChronic DiseaseHumansInflammationLung DiseasesPulmonary Disease, Chronic Obstructivecell metabolismimmune senescenceimmunometabolisminflammagingsenolytic drugssenomorphic drugs

Identifiers

PMID38108546
PMCPMC11497319
OpenAlexW4389892243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.